Quantum Sentinel™
"Simulation-to-Real" Architecture for Predictive Toxicology
The Quantum Sentinel™ platform is engineered to translate the faint magnetic noise of cellular stress into a clear, actionable, and personalized risk score. It is designed to intervene at the earliest stage of cellular injury by detecting the initial oxidative stress, providing a predictive insight that is unavailable through traditional, late-stage biomarker measurements. This page details the core components of our proprietary architecture.
A Fusion of Simulation and Experiment
Our competitive advantage lies in our unique, dual-pronged architecture that bridges physics-first simulation with real-world biological validation. The Computational Prong acts as a data factory, generating a massive library of predicted molecular signatures. The Experimental Prong uses our quantum sensors to measure the real-world signals from live cells. By using the experimental data to continuously validate and refine our computational models, we create a powerful feedback loop that makes our platform more precise with every sample we analyze.
In-Silico Engine: Our Data Factory
Our proprietary computational engine uses a multi-layered workflow to predict and generate the specific magnetic fingerprints for each type of Reactive Oxygen Species (ROS) molecule. This sophisticated, multi-physics pipeline allows us to build an unparalleled data advantage for training our AI classifier. It involves three key stages:
- Quantum Chemistry: We calculate the foundational electronic and magnetic properties of the ROS molecule.
- Molecular Dynamics: We then simulate the molecule's behavior in a realistic, dynamic cellular environment.
- Quantum Simulation: Finally, we simulate how the specific magnetic noise from that molecule affects our NV sensor, creating a unique, predictable signature.
Experimental Platform: Real-World Validation
Our experimental platform provides the ground truth data needed to validate our simulations. We use custom-engineered NV-diamond quantum sensors to measure the real-world ROS burst from live, irradiated human cell cultures. By correlating the acute T1 relaxometry signal we measure within hours to a comprehensive panel of downstream biomarkers of cell death and damage, we can definitively prove the predictive power of our platform.
The Product: The Ex-vivo Radiosensitivity Index
The output of our platform is a tangible clinical report that delivers a personalized Radiation Toxicity Score (RTS), or Radiosensitivity Index. For the first time, oncologists can see a biological test drive of their treatment plan before it begins. This empowers clinicians to move from population-based protocols to evidence-based, personalized therapy, allowing them to tailor a safer, more effective treatment plan from day one by personalizing dosing or prescribing supportive care.
Building Clinical Confidence Through Rigorous Validation
A predictive score is only as good as its validation. Our experimental protocol is designed to prove a statistically significant correlation between the early ROS signature detected by our sensor and a comprehensive panel of established downstream biomarkers of cellular damage. This ensures our predictive insights are grounded in established biology.
Beyond Oncology: A Platform for Proactive Medicine
While our initial focus is in Oncology, the Quantum Sentinel™ platform is a foundational technology with broad applications across medicine. Our ability to provide an early, molecular-level warning of cellular stress is a powerful new toolkit for 21st-century healthcare.
Future Applications include:
Nephrotoxicity Monitoring
Early detection of kidney injury from chemotherapy, contrast agents, and other treatments, enabling intervention before permanent damage occurs.
Drug Development Safety
Real-time monitoring of cellular toxicity during clinical trials, helping our pharmaceutical partners identify safety issues earlier in the development process.
Personalized Radiation Planning
Pre-treatment testing to identify patients at high risk of radiation complications, enabling personalized dosing and prophylactic measures from day one.